Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
06/2012
06/07/2012US20120141537 Enhancing t cell activation using altered mhc-peptide ligands
06/07/2012US20120141536 Use of an adjuvanted allergy vaccine formulation for parenteral administration
06/07/2012US20120141533 Mycobacterial mutants inducing il-12
06/07/2012US20120141531 Composition comprising oil drops
06/07/2012US20120141528 Lyophilized viral formulations
06/07/2012US20120141527 Structured viral peptide compositions and methods of use
06/07/2012US20120141526 Nanoemulsion vaccines
06/07/2012US20120141525 Universal influenza vaccine based on recombinant modified vaccine ankara virus (mva)
06/07/2012US20120141522 Recombinant protective protein from streptococcus pneumoniae
06/07/2012US20120141521 Immunogenic Compositions for Streptococcus agalactiae
06/07/2012US20120141520 Recombinant subunit west nile virus vaccine for protection of human subjects
06/07/2012US20120141519 Reagents and methods for detecting influenza virus proteins
06/07/2012US20120141518 Human Parvovirus: Bocavirus
06/07/2012US20120141516 Compositions and methods for inducing an immune response
06/07/2012US20120141515 Ig-pCONSENSUS GENE VACCINATION PROTECTS FROM ANTIBODY-DEPENDENT IMMUNE PATHOLOGY IN AUTOIMMUNE DISEASE
06/07/2012US20120141514 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
06/07/2012US20120141513 Deuterated fingolimod
06/07/2012US20120141512 Method of increasing immunological effect
06/07/2012US20120141505 Cd19-ligand and use
06/07/2012US20120141487 Moraxella catarrhalis antigens
06/07/2012US20120141482 Molecular complexes which modify immune responses
06/07/2012US20120141475 TNF-alpha Antagonists and Methotrexate in the Treatment of TNF-Mediated Disease
06/07/2012US20120141474 TNF-alpha Antagonists and Methotrexate in the Treatment of TNF-Mediated Disease
06/07/2012US20120141470 T cell inhibitory receptor compositions and uses thereof
06/07/2012US20120141463 Method Of Identifying Membrane Ig Specific Antibodies And Use Thereof For Targeting Immunoglobulin-Producing Precursor Cells
06/07/2012US20120141449 Albumin Fusion Proteins
06/07/2012US20120141446 Oral Nutritional Supplement Delivery System
06/07/2012US20120141443 Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
06/07/2012US20120141415 Albumin Fusion Proteins
06/07/2012US20120141413 Use of il-15 preparations to treat lymphopenia
06/07/2012US20120141411 Uses of IL-174 Antagonists for Inhibiting A Th2 Immune Response
06/07/2012US20120141409 Multi-valent adjuvant display
06/07/2012US20120141401 Soft anticholinergic zwitterions
06/07/2012US20120141392 Methods of modulating the activity of the mc1 receptor and treatment of conditions related to this receptor
06/07/2012US20120141376 Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
06/07/2012US20120141372 RS7 Antibodies
06/07/2012CA2856697A1 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
06/07/2012CA2819520A1 Tolerance induction or immunosupression to prevent in particular graft-versus-host-disease (gvhd) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
06/07/2012CA2819463A1 Tomm34 peptides and vaccines including the same
06/06/2012EP2460830A2 IL-18 binding proteins
06/06/2012EP2460829A2 IL-18 binding proteins
06/06/2012EP2460812A1 Sterol derivatives and their synthesis and use
06/06/2012EP2460805A1 Fused imidazole derivative having ttk inhibitory action
06/06/2012EP2460537A1 Methods for treating conditions associated with MASP-2 dependent complement activation
06/06/2012EP2459594A1 Fully human antibodies to btla
06/06/2012EP2459572A2 Spirocyclic amide derivatives
06/06/2012EP2459566A1 Tricyclic inhibitors of jak
06/06/2012EP2459556A1 2, 7 -naphthyridin- 1 -one derivatives as syk kinase inhibitors
06/06/2012EP2459543A1 Benzo [e][1, 3]oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
06/06/2012EP2459222A1 Sticky soft gel for treating poultry
06/06/2012EP2459196A1 Plk inhibitor salts
06/06/2012EP2459184A1 Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
06/06/2012EP2001842B1 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
06/06/2012EP1575526B1 Dna vaccines encoding heat shock proteins
06/06/2012CN1561343B Soluble T cell receptor
06/06/2012CN102485267A Tibetan-Miao medicine for treating child cough caused by allergy, viruses, and bacteria
06/06/2012CN102485266A Formula of five-tree sap oral liquid having effects of enhancing immunity, delaying senescence, maintaining beauty and keeping young
06/06/2012CN101849902B Preparation method of solid pharmaceutical composition containing desloratadine
06/06/2012CN101690812B Concentrated freeze-dried yolk antibody composite preparation for Newcastle disease-infectious bursal disease and preparation process thereof
06/06/2012CN101544693B Recombined extrasin alpha 1 two-strand body protein and preparation method thereof
06/06/2012CN101511369B Methods and compositions for inhibiting angiogenesis.
06/06/2012CN101440116B Glycyrrhizin, preparation and use thereof
06/06/2012CN101437834B Modulation of cytokine signaling regulators and applications for immunotherapy
06/06/2012CN101386642B Expression of vibrio alginolyticus outer membrane protein VA0760 and application thereof as vaccine component
06/06/2012CN101039933B Diaminotriazole compounds useful as protein kinase inhibitors
06/05/2012US8193249 Triptolide analogs for the treatment of autoimmune and inflammatory disorders
06/05/2012US8193199 Heterocyclic compounds and their uses
06/05/2012US8193183 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists
06/05/2012US8193164 Organic compounds
06/05/2012US8192753 pH-sensitive cationic lipids, and liposomes and nanocapsules containing the same
06/05/2012US8192732 Mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
06/05/2012CA2571019C 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
06/05/2012CA2567976C A composition having immunoregulating activities comprising lactobacillus pentosus
06/05/2012CA2557275C Bicyclo derivative
06/05/2012CA2507530C Rapamycin and il-10 for the treatment of immune diseases
06/05/2012CA2482041C 4-chromanone derivatives for treating cellular proliferative diseases and disorders
06/05/2012CA2435375C Mammalian tumor susceptibility gene products and their uses
06/05/2012CA2423983C An immunogenic iscom complex comprising an enzymatically active a1 subunit of the cholera toxin or e. coli heat labile enterotoxin fused to a dimer of the d region of protein a
06/05/2012CA2406278C Inhibitors of human phosphatidyl-inositol 3-kinase delta
06/05/2012CA2403701C Recombinant parainfluenza virus expression systems and vaccines
06/05/2012CA2397359C Composition of antigen and glycolipid adjuvant sublingual administration
06/05/2012CA2324226C Inhibitors of caspases
06/05/2012CA2249352C Immunoliposomes that optimize internalization into target cells
06/05/2012CA2248667C Hla-a2.1 binding peptides and their uses
05/2012
05/31/2012WO2012071374A1 Methods of treatment using selective bcl-2 inhibitors
05/31/2012WO2012071336A1 Salts and crystalline forms of an apoptosis-inducing agent
05/31/2012WO2012071186A1 Modulators of s1p receptors
05/31/2012WO2012070649A1 Highly-soluble pyrroloquinoline quinone salt and method for producing same
05/31/2012WO2012070059A1 Fingolimod polymorphs and their processes
05/31/2012WO2012069658A2 Immunomodulatory compositions
05/31/2012WO2012069525A1 Inhibitors of sp140 and their use in therapy
05/31/2012WO2012069202A1 Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors
05/31/2012WO2012047848A3 Allergen deactivator composition, articles and methods
05/31/2012WO2012047017A3 2,3-dihydro-isoindol-1-one derivative and a composition comprising the same
05/31/2012WO2012033348A3 Composition for the prevention or treatment of allergic diseases comprising 2-linoleoyl glycerol
05/31/2012US20120136338 Immunologic compounds for prevention, protection, prophylaxis or treatment of immunological disorders, infections and cancer
05/31/2012US20120136142 Vaccine Compositions For Marburg Virus
05/31/2012US20120136044 Compositions And Methods Of Inhibiting NADPH Oxidase Expression
05/31/2012US20120136026 5-membered heterocyclic compound cyclopenta[c]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof
05/31/2012US20120136013 Organic compounds
1 ... 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 ... 1172